



PRESS RELEASE

AB SCIENCE TO HOLD ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS ON JUNE 30, 2023

Paris, May 30, 2023, 6.30pm CET

AB Science SA (Euronext - FR0010557264 - AB) will hold its Annual General Meeting (AGM) on Friday 30 June 2023 at 3.30pm at the offices of the law firm Levine Keszler, located on the 1st floor, 11, rue Auber - 75009 Paris.

The Notice of Meeting of this AGM was published on May 26, 2023 in the French legal bulletin. It includes the agenda, the proposed resolutions as well as instructions to participate and vote in this AGM. All documentation regarding this AGM will be published on the Company's website along with the dial-in details for the live broadcast.

Precision regarding the AGM:

Only shareholders having registered their shares at least two business days prior to the date of the AGM, by zero hour Paris time, will be able to participate.

Shareholders holding "au porteur" (bearer) shares will need to obtain an "attestation de participation" (certificate of shareholding) from their brokers. This "attestation de participation" must be attached to the voting or proxy form.

Written questions from shareholders must be received the second business days prior to the AGM at the latest (by e-mail to investors@ab-science.com).

Shareholders may obtain the legal documentation in preparation of the AGM (as described in article R. 225-83 of the French Code de Commerce) by sending a request by e-mail to investors@ab-science.com.

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science's website: www.ab-science.com.

Forward-looking Statements - AB Science

This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.

These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are

reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

AB Science

Financial Communication & Media Relations

investors@ab-science.com